CN104619725B - 抗-dr5家族抗体，双特异性或多价抗-dr5家族抗体及其应用方法 - Google Patents

抗-dr5家族抗体，双特异性或多价抗-dr5家族抗体及其应用方法 Download PDF

Info

Publication number
CN104619725B
CN104619725B CN201380036952.2A CN201380036952A CN104619725B CN 104619725 B CN104619725 B CN 104619725B CN 201380036952 A CN201380036952 A CN 201380036952A CN 104619725 B CN104619725 B CN 104619725B
Authority
CN
China
Prior art keywords
antibody
seq
chain
sequence seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380036952.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104619725A (zh
Inventor
克劳丁·布丽奇特·费尔南德·瓦瑞默特-迪斯洛契斯
奥利维尔·弗里德里克·素贝格
劳伦斯·弗朗索瓦丝·珍妮-玛丽·布尔丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jian Ma Protects Holdings Ltd
Original Assignee
Jian Ma Protects Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jian Ma Protects Holdings Ltd filed Critical Jian Ma Protects Holdings Ltd
Publication of CN104619725A publication Critical patent/CN104619725A/zh
Application granted granted Critical
Publication of CN104619725B publication Critical patent/CN104619725B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380036952.2A 2012-07-09 2013-07-09 抗-dr5家族抗体，双特异性或多价抗-dr5家族抗体及其应用方法 Active CN104619725B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305821.6 2012-07-09
EP12305821.6A EP2684896A1 (en) 2012-07-09 2012-07-09 Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US201261669866P 2012-07-10 2012-07-10
US61/669866 2012-07-10
PCT/EP2013/064466 WO2014009358A1 (en) 2012-07-09 2013-07-09 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
CN104619725A CN104619725A (zh) 2015-05-13
CN104619725B true CN104619725B (zh) 2019-04-23

Family

ID=46514282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380036952.2A Active CN104619725B (zh) 2012-07-09 2013-07-09 抗-dr5家族抗体，双特异性或多价抗-dr5家族抗体及其应用方法

Country Status (15)

Country Link
US (4) US9611327B2 (enExample)
EP (3) EP2684896A1 (enExample)
JP (1) JP6457386B2 (enExample)
CN (1) CN104619725B (enExample)
BR (1) BR112015000449B1 (enExample)
CA (1) CA2878790C (enExample)
DK (1) DK2877491T3 (enExample)
ES (1) ES2727486T3 (enExample)
IL (2) IL236651B (enExample)
IN (1) IN2015DN00143A (enExample)
PL (1) PL2877491T3 (enExample)
PT (1) PT2877491T (enExample)
SG (2) SG10201700148UA (enExample)
SI (1) SI2877491T1 (enExample)
WO (1) WO2014009358A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
EP3048116A1 (en) 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
HK1247215A1 (zh) * 2015-01-26 2018-09-21 Macrogenics, Inc. 包含dr5-结合结构域的多价分子
EP3112381A1 (en) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispecific antibodies for use in cancer immunotherapy
SG10201912410TA (en) 2015-07-16 2020-02-27 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins
AU2016363770A1 (en) 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof
CN106397594B (zh) * 2016-10-25 2019-06-04 中国药科大学 一种全人源的抗人死亡受体5的激动剂单链抗体及应用
CN110461868A (zh) 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
CN111328335A (zh) * 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
US20210107988A1 (en) 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
KR20200123782A (ko) * 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
WO2020136218A1 (en) * 2018-12-26 2020-07-02 Imcheck Therapeutics Sas Btn3a binding proteins and uses thereof
EP3966241A1 (en) 2019-05-09 2022-03-16 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
KR20240170601A (ko) * 2022-03-02 2024-12-03 월든 바이오사이언시즈, 인크. 신규한 가용성 유로키나제 플라스미노겐 활성화제 수용체(supar) 결합 분자 및 이의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
EP1500702A1 (en) 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6740739B1 (en) * 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
CA2317727C (en) 1998-01-23 2013-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
IL146491A0 (en) 1999-06-09 2002-07-25 Genentech Inc APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
GB0020442D0 (en) 2000-08-18 2000-10-04 Nokia Networks Oy Data transmission protocol
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CA2599265A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

Also Published As

Publication number Publication date
US20150139997A1 (en) 2015-05-21
US20170260281A1 (en) 2017-09-14
PT2877491T (pt) 2019-06-07
SG11201500177PA (en) 2015-03-30
JP6457386B2 (ja) 2019-01-23
HK1211044A1 (en) 2016-05-13
CA2878790A1 (en) 2014-01-16
IN2015DN00143A (enExample) 2015-06-12
EP2684896A1 (en) 2014-01-15
US10647774B2 (en) 2020-05-12
EP3575323B1 (en) 2024-09-11
PL2877491T3 (pl) 2020-01-31
US9611327B2 (en) 2017-04-04
EP2877491A1 (en) 2015-06-03
EP2877491B1 (en) 2019-02-27
DK2877491T3 (da) 2019-06-03
US20240141057A1 (en) 2024-05-02
JP2015527992A (ja) 2015-09-24
CA2878790C (en) 2023-09-26
BR112015000449A2 (enExample) 2017-08-15
SI2877491T1 (sl) 2019-08-30
US20200332016A1 (en) 2020-10-22
WO2014009358A1 (en) 2014-01-16
BR112015000449B1 (pt) 2022-12-20
CN104619725A (zh) 2015-05-13
SG10201700148UA (en) 2017-02-27
IL236651B (en) 2019-10-31
IL236651A0 (en) 2015-02-26
ES2727486T3 (es) 2019-10-16
IL269527B (en) 2021-12-01
IL269527A (en) 2019-11-28
EP3575323A1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
US20240141057A1 (en) Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
KR102587442B1 (ko) 항-cd47 항체 또는 그 적용
JP7196076B2 (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
EP3750918A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN113645996A (zh) 抗claudin 18抗体及其使用方法
JP2024504471A (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
US12060416B2 (en) Humanized anti-VEGF monoclonal antibody
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
CN114341170B (zh) 一种人源化抗vegfr2抗体及其应用
EP4279507A1 (en) Cd73-binding protein and use thereof
EP4596582A1 (en) B7-h3 binding protein and use thereof
WO2021032174A1 (zh) 一种抗cd47抗原结合蛋白及其应用
CN120239710A (zh) 抗ccr8抗体及其用途
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
HK1211044B (en) Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
JP2022174194A (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法
TW202222840A (zh) Ｃｄ７３的抗原結合蛋白及其應用
HK40086174A (zh) 分离的抗原结合蛋白及其应用
CN115572330A (zh) 一种特异性抗体及其制备方法和应用
HK40064186A (en) Anti-claudin 18 antibodies and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160301

Address after: Utrecht

Applicant after: Jian Ma protects Holdings Limited

Address before: France Dardilly

Applicant before: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH

GR01 Patent grant
GR01 Patent grant
TA01 Transfer of patent application right

Effective date of registration: 20190410

Address after: Utrecht

Applicant after: Jianma Insurance Co., Ltd.

Address before: Utrecht

Applicant before: Jian Ma protects Holdings Limited

TA01 Transfer of patent application right